IP Library › Granted Patent US 12,280,149
Granted Patent B1
US 12,280,149 · App. 18/762,013 · Granted Apr 22, 2025

Manufacturing of bupivacaine multivesicular liposomes

Inventors: Eran Levy (San Diego, CA); Jeffrey S. Hall (San Diego, CA); John J. Grigsby, Jr. (San Diego, CA)
Assignee: Pacira Pharmaceuticals, Inc.
A61K9/1277A61K31/445
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,280,149
App. No.
18/762,013
Granted
Apr 22, 2025
Kind
B1
Abstract

Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

Claims (47)

1. A process for preparing a batch of bupivacaine encapsulated multivesicular liposomes (MVLs), the process comprising:

(a) mixing a first aqueous solution comprising phosphoric acid with a volatile water-immiscible solvent solution to form a water-in-oil first emulsion, wherein the volatile water-immiscible solvent solution comprises 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) (DPPG) or a salt thereof, 1,2-dierucoylphosphatidylcholine (DEPC), tricaprylin and cholesterol, and wherein either the first aqueous solution or the solvent solution comprises bupivacaine;

(b) mixing the water-in-oil first emulsion with a second aqueous solution to form a water-in-oil-in-water second emulsion, wherein the second aqueous solution comprises lysine and at least one osmotic agent;

(c) substantially removing the volatile water-immiscible solvent from the water-in-oil-in-water second emulsion by sparging the water-in-oil-in-water second emulsion to form a first aqueous suspension of bupivacaine encapsulated MVLs having a first volume;

(d) reducing the first volume of the first aqueous suspension of bupivacaine encapsulated multivesicular liposomes by a first microfiltration to provide a second aqueous suspension of bupivacaine encapsulated MVLs having a second volume, wherein the first microfiltration feed flow rate is about 200 L/min to about 400 L/min;

(e) exchanging the second aqueous suspension medium with a saline solution by diafiltration to provide a third aqueous suspension of bupivacaine encapsulated MVLs having a third volume, wherein the diafiltration feed flow rate is about 200 L/min to about 350 L/min; and

(f) reducing the third volume of the third aqueous suspension by a second microfiltration to provide a batch of aqueous suspension of bupivacaine encapsulated MVLs having a target concentration of bupivacaine from 12 mg/mL to 17 mg/mL;

wherein the batch has a volume of at least 100 liters to about 300 liters;

wherein the batch has a cumulative percentage release of bupivacaine from 46% to 71% at a 24-hour time point, measured from two to six aliquots of the batch using a rotator-facilitated in vitro release assay for at least 48 hours, after storage of the aliquots at 2° C. to 8° C. for about 12 months from batch manufacture date; and

wherein the rate of change in the cumulative percentage release of bupivacaine at the 24-hour time point is 0.05%/month to 0.5%/month after storage of the aliquots at 2° C. to 8° C. for about 12 months.

2. The process of claim 1 , wherein the rate of change in the cumulative percentage release of bupivacaine at the 24-hour time point is 0.08%/month to 0.5%/month.

3. The process of claim 2 , wherein the rate of change in the cumulative percentage release of bupivacaine at the 24-hour time point is 0.1%/month to 0.4%/month.

4. The process of claim 1 , wherein the batch has a cumulative percentage release of bupivacaine from 60% to 85% at the 48-hour time point, and the rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is −0.3%/month to 0.33%/month after storage of the aliquots at 2° C. to 8° C. for about 12 months.

5. The process of claim 4 , wherein the rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is −0.2%/month to 0.30%/month.

6. The process of claim 5 , wherein the rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is from −0.12%/month to 0.28%/month.

7. The process of claim 1 , wherein the cumulative percentage release of bupivacaine of the batch is measured as the average of six aliquots.

8. The process of claim 1 , wherein each aliquot has a cumulative percentage release of bupivacaine from 36% to 81% at the 24-hour time point.

9. The process of claim 8 , wherein each aliquot has a cumulative percentage release of bupivacaine from 50% to 95% at the 48-hour time point.

10. The batch of claim 1 , wherein the total bupivacaine concentration in the composition is about 13.3 mg/mL.

11. The process of claim 1 , wherein the mixing in step (a) is performed at a high speed from about 1100 rpm to about 1300 rpm for about 65 minutes to about 75 minutes.

12. The process of claim 1 , wherein the mixing in step (b) is performed at a low speed from about 445 rpm to about 680 rpm for about 60 to about 85 seconds.

13. A process for preparing a batch of bupivacaine encapsulated multivesicular liposomes (MVLs), the process comprising:

(a) mixing a first aqueous solution comprising phosphoric acid with a volatile water-immiscible solvent solution to form a water-in-oil first emulsion, wherein the volatile water-immiscible solvent solution comprises 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) (DPPG) or a salt thereof, 1,2-dierucoylphosphatidylcholine (DEPC), tricaprylin and cholesterol, and wherein either the first aqueous solution or the solvent solution comprises bupivacaine;

(b) mixing the water-in-oil first emulsion with a second aqueous solution to form a water-in-oil-in-water second emulsion, wherein the second aqueous solution comprises lysine and at least one osmotic agent;

(c) substantially removing the volatile water-immiscible solvent from the water-in-oil-in-water second emulsion by sparging the water-in-oil-in-water second emulsion to form a first aqueous suspension of bupivacaine encapsulated MVLs having a first volume;

(d) reducing the first volume of the first aqueous suspension of bupivacaine encapsulated multivesicular liposomes by a first microfiltration to provide a second aqueous suspension of bupivacaine encapsulated MVLs having a second volume, wherein the first microfiltration feed flow rate is about 200 L/min to about 400 L/min;

(e) exchanging the second aqueous suspension medium with a saline solution by diafiltration to provide a third aqueous suspension of bupivacaine encapsulated MVLs having a third volume, wherein the diafiltration feed flow rate is about 200 L/min to about 350 L/min; and

(f) reducing the third volume of the third aqueous suspension by a second microfiltration to provide a batch of aqueous suspension of bupivacaine encapsulated MVLs having a target concentration of bupivacaine from 12 mg/mL to 17 mg/mL;

wherein the batch has a volume of at least 100 liters to about 300 liters;

wherein the batch has a cumulative percentage release of bupivacaine from 60% to 85% at a 48-hour time point, measured from two to six aliquots of the batch using a rotator-facilitated in vitro release assay for at least 48 hours, after storage of the aliquots at 2° C. to 8° C. for about 12 months from batch manufacture date; and

wherein the rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is −0.18%/month to 0.33%/month after storage of the aliquots at 2° C. to 8° C. for about 12 months.

14. The process of claim 13 , wherein the rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is-0.15%/month to 0.30%/month.

15. The process of claim 14 , wherein the rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is from −0.12%/month to 0.28%/month.

16. The process of claim 13 , wherein the cumulative percentage release of bupivacaine of the batch is measured as the average of six aliquots.

17. The process of claim 13 , wherein each aliquot has a cumulative percentage release of bupivacaine from 36% to 81% at the 24-hour time point.

18. The process of claim 17 , wherein each aliquot has a cumulative percentage release of bupivacaine from 50% to 95% at the 48-hour time point.

19. The process of claim 13 , wherein the bupivacaine concentration in the composition is about 13.3 mg/mL.

20. The process of claim 13 , wherein the mixing in step (a) is performed at a high speed from about 1100 rpm to about 1300 rpm for about 65 minutes to about 75 minutes.

21. The process of claim 13 , wherein the mixing in step (b) is performed at a low speed from about 445 rpm to about 680 rpm for about 60 to about 85 seconds.

22. The process of claim 1 , wherein the batch has a volume of about 110 L to about 250 L.

23. The process of claim 1 , wherein the first microfiltration feed flow rate comprises a beginning first microfiltration feed flow rate from about 290 L/min to about 350 L/min, and an end first microfiltration feed flow rate from about 250 L/min to about 310 L/min.

24. The process of claim 1 , wherein the diafiltration feed flow rate comprises a first stage diafiltration feed flow rate from about 250 L/min to 310 L/min.

25. The process of claim 13 , wherein the batch has a volume of about 110 L to about 250 L.

26. The process of claim 13 , wherein the first microfiltration feed flow rate comprises a beginning first microfiltration feed flow rate from about 290 L/min to about 350 L/min, and an end first microfiltration feed flow rate from about 250 L/min to about 310 L/min.

27. The process of claim 13 , wherein the diafiltration feed flow rate comprises a first stage diafiltration feed flow rate from about 250 L/min to 310 L/min.

28. The process of claim 23 , wherein the diafiltration feed flow rate comprises a first stage diafiltration feed flow rate from about 250 L/min to 310 L/min, and a second stage feed flow rate from about 245 L/min to about 265 L/min.

29. The process of claim 26 , wherein the diafiltration feed flow rate comprises a first stage diafiltration feed flow rate from about 250 L/min to 310 L/min, and a second stage feed flow rate from about 245 L/min to about 265 L/min.

Assignments (2)
SECURITY INTEREST Recorded Jul 4, 2025
From: PACIRA PHARMACEUTICALS, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 071814/0792 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2024
From: LEVY, ERAN; HALL, JEFFREY S.; GRIGSBY, JOHN J., JR.
To: PACIRA PHARMACEUTICALS, INC.
Reel/Frame 068889/0638 →
Continuity (1)
Provisional Application 63649846 · May 20, 2024
References Cited (387)
US 3684251A · Bowling · 1972 [cited by applicant]
US 3946994A · Mertz et al. · 1976 [cited by applicant]
US 4026817A · Ciuti et al. · 1977 [cited by applicant]
US 4078052A · Papahadjopoulos · 1978 [cited by applicant]
US 4089801A · Schneider · 1978 [cited by applicant]
US 4113765A · Richardson et al. · 1978 [cited by applicant]
US 4145410A · Sears · 1979 [cited by applicant]
US 4224179A · Schneider · 1980 [cited by applicant]
US 4235587A · Miles · 1980 [cited by applicant]
US 4235871A · Papahadjopoulos et al. · 1980 [cited by applicant]
US 4310506A · Baldeschwieler et al. · 1982 [cited by applicant]
US 4394372A · Taylor · 1983 [cited by applicant]
US 4420398A · Castino · 1983 [cited by applicant]
US 4454083A · Brown et al. · 1984 [cited by applicant]
US 4478824A · Franco et al. · 1984 [cited by applicant]
US 4522803A · Lenk et al. · 1985 [cited by applicant]
US 4588578A · Fountain et al. · 1986 [cited by applicant]
US 4590030A · Gillner et al. · 1986 [cited by applicant]
US 4599227A · Dees et al. · 1986 [cited by applicant]
US 4599342A · LaHann · 1986 [cited by applicant]
US 4610868A · Fountain et al. · 1986 [cited by applicant]
US 4622219A · Haynes · 1986 [cited by applicant]
US 4644056A · Kothe et al. · 1987 [cited by applicant]
US 4652441A · Okada et al. · 1987 [cited by applicant]
US 4668580A · Dahm et al. · 1987 [cited by applicant]
US 4711782A · Okada et al. · 1987 [cited by applicant]
US 4725442A · Haynes · 1988 [cited by applicant]
US 4744989A · Payne et al. · 1988 [cited by applicant]
US 4752425A · Martin et al. · 1988 [cited by applicant]
US 4761255A · Dahm et al. · 1988 [cited by applicant]
US 4761288A · Mezei · 1988 [cited by applicant]
US 4769250A · Forssen · 1988 [cited by applicant]
US 4776991A · Farmer et al. · 1988 [cited by applicant]
US 4781831A · Goldsmith · 1988 [cited by applicant]
US 4781871A · West, III et al. · 1988 [cited by applicant]
US 4788001A · Narula · 1988 [cited by applicant]
US 4844620A · Lissant et al. · 1989 [cited by applicant]
US 4844904A · Hamaguchi et al. · 1989 [cited by applicant]
US 4861597A · Kida et al. · 1989 [cited by applicant]
US 4877561A · Iga et al. · 1989 [cited by applicant]
US 4877619A · Richer · 1989 [cited by applicant]
US 4908463A · Bottelberghe · 1990 [cited by applicant]
US 4920016A · Allen et al. · 1990 [cited by applicant]
US 4921644A · Lau et al. · 1990 [cited by applicant]
US 4921853A · LeBlanc · 1990 [cited by applicant]
US 4937078A · Mezei et al. · 1990 [cited by applicant]
US 4946683A · Forssen · 1990 [cited by applicant]
US 4956290A · Harrison et al. · 1990 [cited by applicant]
US 5000959A · Iga et al. · 1991 [cited by applicant]
US 5004611A · Leigh · 1991 [cited by applicant]
US 5013556A · Woodle et al. · 1991 [cited by applicant]
US 5019394A · Hamaguchi et al. · 1991 [cited by applicant]
US 5021200A · Vanlerberghe et al. · 1991 [cited by applicant]
US 5049392A · Weiner et al. · 1991 [cited by applicant]
US 5069936A · Yen · 1991 [cited by applicant]
US 5077056A · Bally et al. · 1991 [cited by applicant]
US 5091187A · Haynes · 1992 [cited by applicant]
US 5094854A · Ogawa et al. · 1992 [cited by applicant]
US 5100591A · Leclef et al. · 1992 [cited by applicant]
US 5141674A · Leigh · 1992 [cited by applicant]
US 5147134A · Bradley et al. · 1992 [cited by applicant]
US 5169637A · Lenk et al. · 1992 [cited by applicant]
US 5186941A · Callahan et al. · 1993 [cited by applicant]
US 5192549A · Barenolz et al. · 1993 [cited by applicant]
US 5204112A · Hope et al. · 1993 [cited by applicant]
US 5211955A · Legros et al. · 1993 [cited by applicant]
US 5225212A · Martin et al. · 1993 [cited by applicant]
US 5227165A · Domb et al. · 1993 [cited by applicant]
US 5227170A · Sullivan · 1993 [cited by applicant]
US 5244678A · Legros et al. · 1993 [cited by applicant]
US 5246707A · Haynes · 1993 [cited by applicant]
US 5261903A · Dhaliwal et al. · 1993 [cited by applicant]
US 5292701A · Glemza et al. · 1994 [cited by applicant]
US 5321012A · Mayer et al. · 1994 [cited by applicant]
US 5334381A · Unger · 1994 [cited by applicant]
US 5334391A · Clark et al. · 1994 [cited by applicant]
US 5364632A · Benita et al. · 1994 [cited by applicant]
US 5387387A · James et al. · 1995 [cited by applicant]
US 5393530A · Schneider et al. · 1995 [cited by applicant]
US 5407660A · Bosworth et al. · 1995 [cited by applicant]
US 5415867A · Minchey et al. · 1995 [cited by applicant]
US 5422120A · Kim · 1995 [cited by applicant]
US 5451408A · Mezei et al. · 1995 [cited by applicant]
US 5455044A · Kim et al. · 1995 [cited by applicant]
US RE35192E · Reese · 1996 [cited by applicant]
US 5533526A · Goldberg · 1996 [cited by applicant]
US 5543158A · Gref et al. · 1996 [cited by applicant]
US 5576017A · Kim · 1996 [cited by applicant]
US 5576018A · Kim et al. · 1996 [cited by applicant]
US 5589189A · Moynihan · 1996 [cited by applicant]
US 5635205A · Nyqvist et al. · 1997 [cited by applicant]
US 5658898A · Weder et al. · 1997 [cited by applicant]
US 5662931A · Munechika et al. · 1997 [cited by applicant]
US 5681464A · Larsson · 1997 [cited by applicant]
US 5700482A · Frederiksen et al. · 1997 [cited by applicant]
US 5708011A · Bardsley et al. · 1998 [cited by applicant]
US 5723147A · Kim et al. · 1998 [cited by applicant]
US 5766627A · Sankaram et al. · 1998 [cited by applicant]
US 5770222A · Unger et al. · 1998 [cited by applicant]
US 5776486A · Castor et al. · 1998 [cited by applicant]
US 5776915A · Peterson et al. · 1998 [cited by applicant]
US 5807573A · Ljusberg-Wahren et al. · 1998 [cited by applicant]
US 5814335A · Webb et al. · 1998 [cited by applicant]
US 5827533A · Needham · 1998 [cited by applicant]
US 5837282A · Fenske et al. · 1998 [cited by applicant]
US 5849763A · Bardsley et al. · 1998 [cited by applicant]
US 5853755A · Foldvari · 1998 [cited by applicant]
US 5865184A · Takiguchi · 1999 [cited by applicant]
US 5879672A · Davis et al. · 1999 [cited by applicant]
US 5882679A · Needham · 1999 [cited by applicant]
US 5885260A · Mehl, Sr. et al. · 1999 [cited by applicant]
US 5891467A · Willis · 1999 [cited by applicant]
US 5891842A · Kream · 1999 [cited by applicant]
US 5895661A · Tournier et al. · 1999 [cited by applicant]
US 5910502A · Gennery · 1999 [cited by applicant]
US 5912271A · Brodin et al. · 1999 [cited by applicant]
US 5919804A · Gennery · 1999 [cited by applicant]
US 5922340A · Berde et al. · 1999 [cited by applicant]
US 5942253A · Gombotz et al. · 1999 [cited by applicant]
US 5945126A · Thanoo et al. · 1999 [cited by applicant]
US 5945435A · Evetts · 1999 [cited by applicant]
US 5947689A · Schick · 1999 [cited by applicant]
US 5948441A · Lenk et al. · 1999 [cited by applicant]
US 5955087A · Whittle et al. · 1999 [cited by applicant]
US 5955479A · Bardsley et al. · 1999 [cited by applicant]
US 5962016A · Willis · 1999 [cited by applicant]
US 5962532A · Campbell et al. · 1999 [cited by applicant]
US 5977326A · Scheinmann et al. · 1999 [cited by applicant]
US 5980927A · Nelson et al. · 1999 [cited by applicant]
US 5980937A · Tournier et al. · 1999 [cited by applicant]
US 5997899A · Ye et al. · 1999 [cited by applicant]
US 6007838A · Alving et al. · 1999 [cited by applicant]
US 6033708A · Kwasiborski et al. · 2000 [cited by applicant]
US 6045824A · Kim et al. · 2000 [cited by applicant]
US 6046187A · Berde et al. · 2000 [cited by applicant]
US 6048545A · Keller et al. · 2000 [cited by applicant]
US 6066331A · Barenholz et al. · 2000 [cited by applicant]
US 6069155A · Mather et al. · 2000 [cited by applicant]
US 6071534A · Kim et al. · 2000 [cited by applicant]
US 6103741A · Bardsley et al. · 2000 [cited by applicant]
US 6106858A · Ye et al. · 2000 [cited by applicant]
US 6120797A · Meers et al. · 2000 [cited by applicant]
US 6132766A · Sankaram et al. · 2000 [cited by applicant]
US 6149937A · Camu et al. · 2000 [cited by applicant]
US 6171613B1 · Ye et al. · 2001 [cited by applicant]
US 6193998B1 · Ye et al. · 2001 [cited by applicant]
US 6217899B1 · Benameur et al. · 2001 [cited by applicant]
US 6221385B1 · Camu et al. · 2001 [cited by applicant]
US 6221401B1 · Zasadzinski et al. · 2001 [cited by applicant]
US 6238702B1 · Berde et al. · 2001 [cited by applicant]
US 6241999B1 · Ye et al. · 2001 [cited by applicant]
US 6264988B1 · Yen · 2001 [cited by applicant]
US 6270802B1 · Thanoo et al. · 2001 [cited by applicant]
US 6287587B2 · Shigeyuki et al. · 2001 [cited by applicant]
US 6306432B1 · Shirley et al. · 2001 [cited by applicant]
US 6355267B1 · Collins · 2002 [cited by applicant]
US 6399094B1 · Brandl et al. · 2002 [cited by applicant]
US 6417201B1 · Bardsley et al. · 2002 [cited by applicant]
US 8182835B2 · Kim et al. · 2012 [cited by applicant]
US 8834921B2 · Kim et al. · 2014 [cited by applicant]
US 9192575B2 · Kim et al. · 2015 [cited by applicant]
US 9205052B2 · Kim et al. · 2015 [cited by applicant]
US 9585838B2 · Hartounian et al. · 2017 [cited by applicant]
US 9730892B2 · Schutt et al. · 2017 [cited by applicant]
US 9724302B2 · Schutt et al. · 2017 [cited by applicant]
US 9737482B2 · Schutt et al. · 2017 [cited by applicant]
US 9737483B2 · Schutt et al. · 2017 [cited by applicant]
US 9757336B2 · Schutt et al. · 2017 [cited by applicant]
US 9808424B2 · Schutt et al. · 2017 [cited by applicant]
US 10045941B2 · Schutt et al. · 2018 [cited by applicant]
US 10398648B2 · Schutt et al. · 2019 [cited by applicant]
US 10842745B2 · Barenholz et al. · 2020 [cited by applicant]
US 11033495B1 · Hall et al. · 2021 [cited by applicant]
US 11185506B1 · Hall et al. · 2021 [cited by applicant]
US 11179336B1 · Hall et al. · 2021 [cited by applicant]
US 11278494B1 · Hall et al. · 2022 [cited by applicant]
US 11304904B1 · Hall et al. · 2022 [cited by applicant]
US 11311486B1 · Hall et al. · 2022 [cited by applicant]
US 11357727B1 · Hall et al. · 2022 [cited by applicant]
US 11426348B2 · Hall et al. · 2022 [cited by applicant]
US 11452691B1 · Hall et al. · 2022 [cited by applicant]
US 11819574B2 · Hall et al. · 2023 [cited by applicant]
US 11819575B2 · Hall et al. · 2023 [cited by applicant]
US 11925706B2 · Hall et al. · 2024 [cited by applicant]
US 12156940B1 · Levy · 2024 [cited by examiner]
US 20020039596A1 · Hartounian et al. · 2002 [cited by applicant]
US 20020041895A1 · Gregoriadis et al. · 2002 [cited by applicant]
US 20030201230A1 · Kopf · 2003 [cited by applicant]
US 20040247659A1 · Eibl · 2004 [cited by applicant]
US 20100305160A1 · Brummett · 2010 [cited by applicant]
US 20110244029A1 · Barenholz et al. · 2011 [cited by applicant]
US 20110250264A1 · Schutt et al. · 2011 [cited by applicant]
US 20130177633A1 · Schutt et al. · 2013 [cited by applicant]
US 20130177634A1 · Schutt et al. · 2013 [cited by applicant]
US 20130177637A1 · Schutt et al. · 2013 [cited by applicant]
US 20130189350A1 · Garcia et al. · 2013 [cited by applicant]
US 20130195965A1 · Schutt et al. · 2013 [cited by applicant]
US 20130251786A1 · Li · 2013 [cited by applicant]
US 20130306759A1 · Schutt et al. · 2013 [cited by applicant]
US 20140004173A1 · Hartounian et al. · 2014 [cited by applicant]
US 20140319045A1 · Shevitz · 2014 [cited by applicant]
US 20150158907A1 · Zhou · 2015 [cited by applicant]
US 20180161275A1 · Los et al. · 2018 [cited by applicant]
US 20190169559A1 · Coffman · 2019 [cited by applicant]
US 20190314281A1 · Ma et al. · 2019 [cited by applicant]
US 20220233446A1 · Hall et al. · 2022 [cited by applicant]
US 20220304932A1 · Hall · 2022 [cited by examiner]
US 20230248648A1 · Hall et al. · 2023 [cited by applicant]
US 20230301916A1 · Hall et al. · 2023 [cited by applicant]
CA 2078666 · 1991 [cited by applicant]
CA 1323568 · 1993 [cited by applicant]
CA 2176712 · 1995 [cited by applicant]
CA 1337273 · 1995 [cited by applicant]
CA 2199004 · 2000 [cited by applicant]
CN 110179752A · 2019 [cited by applicant]
CN 108078929B · 2021 [cited by applicant]
EP 0126580 · 1984 [cited by applicant]
EP 0208450 · 1987 [cited by applicant]
EP 0506639 · 1992 [cited by applicant]
EP 0280503 · 1993 [cited by applicant]
EP 0752245 · 1997 [cited by applicant]
EP 3572070 · 2019 [cited by applicant]
GB 2050287 · 1981 [cited by applicant]
WO WO8503011 · 1985 [cited by applicant]
WO WO8900846 · 1989 [cited by applicant]
WO WO8904656 · 1989 [cited by applicant]
WO WO9114445 · 1991 [cited by applicant]
WO WO9300888 · 1993 [cited by applicant]
WO WO9408565 · 1994 [cited by applicant]
WO WO9408626 · 1994 [cited by applicant]
WO WO9422430 · 1994 [cited by applicant]
WO WO9423697 · 1994 [cited by applicant]
WO WO9426250 · 1994 [cited by applicant]
WO WO9426253 · 1994 [cited by applicant]
WO WO9427581 · 1994 [cited by applicant]
WO WO9501164 · 1995 [cited by applicant]
WO WO9513796 · 1995 [cited by applicant]
WO WO9608235 · 1996 [cited by applicant]
WO WO9614057 · 1996 [cited by applicant]
WO WO9702022 · 1997 [cited by applicant]
WO WO9703652 · 1997 [cited by applicant]
WO WO9735561 · 1997 [cited by applicant]
WO WO98014171 · 1998 [cited by applicant]
WO WO98033483 · 1998 [cited by applicant]
WO WO12109387 · 2012 [cited by applicant]
WO WO2111299 · 2021 [cited by applicant]
Kapoor et al., May 2017, Liposomal Drug Product Development and Quality: Current US Experience and Perspective, The AAPS Journal, 19(3):632-641. [cited by applicant]
Opinion in United States District Court, District of New Jersey, Civil Action No. 21-19829-MCA-JRA, dated Aug. 9, 2024, 40 pp. [cited by applicant]
Order in Civil Action No. 21-19829-MCA-JRA, dated Aug. 9, 2024, 2 pp. [cited by applicant]
“Guidance for Industry: Guideline on Sterile Drug Products Produced by Aseptic Processing,” Jun. 1987, Reprinted Jun. 1991, pp. 1-43, Center for Drug Evaluation and Research et al. [cited by applicant]
“Local Anesthetics,” NEW Pharmacology, Revised 3.sup.rd ed., pp. 261-266, Tanaka et al. eds. Nankoudou Corp., Aug. 1, 1997. [cited by applicant]
Andrews et al., “Boundary Layer Solution for a Bubble Rising Through a Liquid Containing Surface-Active Contaminants,” Ind. Eng. Chem. Res., 1995, 34(4):1371-1382. [cited by applicant]
Arroyo et al., “Use of intermittent jets to enhance flux in crossflow filtration,” J. Membrane Sci., 1993, 80:117-129. [cited by applicant]
Assil et al., “Liposome Suppression of Proliferative Vitreoretinopathy: Rabbit Model Using Antimetabolite Encapsulated Liposomes,” Invest. Ophthalmol. Vis. Sci., 32(11):2891-2897, 1991. [cited by applicant]
Assil et al., “Multivesicular Liposomes: Sustained Release of the Antimetabolite Cytarabine in the Eye,” Arch Ophthalmol., 1987, 105(3):400-403. [cited by applicant]
Assil et al., “Tobramycin Liposomes: Single Subconjunctival Therapy of Pseudomonal Keratitis,” Invest. Ophthalmol. Vis. Sci., 32(13):3216-3220, 1991. [cited by applicant]
Bangham et al., “Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids,” J. Mol. Biol., 1965, 13:238-252. [cited by applicant]
Barbet et al., “Weak acid-induced release of liposome-encapsulated carboxyfluorescein,” Biochim. Biophys. Acta, 1984, 772:347-356. [cited by applicant]
Bhave, “Cross-Flow Filtration,” Fermentation and Biochemical Engineering Handbook: Principles, Process Design and Equipment, 2.sup.nd edition, (Vogel et al. Eds., 1997), Noyes Publications, Westwood, New Jersey, pp. 271… [cited by applicant]
Bonetti et al., “An extended-release formulation of methotrexate for subcutaneous administration,” Cancer Chemother. Pharmacol., 33:303-306, 1994. [cited by applicant]
Boogaerts et al. “Biodistribution of liposome-associated bupivacaine after extradural administration to rabbits,” Br. J. Anaesth, 1995, 75:319-325. [cited by applicant]
Boogaerts et al. “Epidural Administration of Liposome-Associated Bupivacaine for the Management of Postsurgical Pain: A First Study,” J. Clin. Anesth, 1994, 6:315-320. [cited by applicant]
Boogaerts et al. “Motor Blockade and Absence of Local Nerve Toxicity Induced by Liposomal Bupivacaine Injected into the Axillary Plexus of Rabbits,” Acta Anesth. Belg., 1995, 46:19-24. [cited by applicant]
Boogaerts et al. “Plasma concentrations of bupivacaine after brachial plexus administration of liposome-associated and plain solutions to rabbits,” Can. J. Anaesth, 1993, 40:1201-1204. [cited by applicant]
Boogaerts et al. “Toxicity of Bupivacaine Encapsulated into Liposomes and Injected Intravenously: Comparison with Plan Solutions,” Anesth. Analg., 1993, 76:553-555. [cited by applicant]
Chamberlain et al., “Treatment of Leptomeningeal Metastasis With Intraventricular Administration of Depot Cytarabine (DTC 101): A Phase I Study,” Arch. Neurol., 50:261-264, 1993. [cited by applicant]
Chatelut et al., “A slow-release methotrexate formulation for intrathecal chemotherapy,” Cancer Chemother. Pharmacol., 32: 179-182, 1993. [cited by applicant]
Chattopadhyay et al., “The Protective Effect of Specific Medium Additives with Respect to Bubble Rupture,” Biotechnol. Bioeng., 1995, 45(6):473-480. [cited by applicant]
Chemical Comprehensive Dictionary, compact 2.sup.rd ed., Kyoritsushuppan Corp., edited by the Editorial Committee of the Chemical Comprehensive Dictionary, Aug. 25, 1963, pp. 725-726. [cited by applicant]
Cherry et al., “Cell Death in the Thin Films of Bursting Bubbles,” Biotechnol. Prog., 1992, 8(1):11-18. [cited by applicant]
Cullis et al., “Structural Properties and Functional Roles of Phospholipids in Biological Membranes,” Phospholipids and Cellular Regulation, pp. 1-59, vol. 1, J.F. Kuo ed., CRC Press, 1985, Boca Raton, FL. [cited by applicant]
Davidson et al., 2010, High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans, Anesthe… [cited by applicant]
De Gier, J et al., Lipid Composition and Permeability of Liposomes, Biochim. Biophys. Acta 150:666-675 (1968). [cited by applicant]
Edwards et al., “Large Porous Particles for Pulmonary Drug Delivery,” Science, 1997, 276: 1868-1871. [cited by applicant]
Frucht-Perry et al., “Fibrin-Enmeshed Tobramycin Liposomes: Single Application Topical Therapy of Pseudomonas Keratitis,” Cornea, 1992, 11(5):393-397. [cited by applicant]
Genovesi, “Several uses for tangential-flow filtration in the pharmaceutical industry,” J. Parenter. Sci. Technol. (1983), 37(3):81-86. [cited by applicant]
Grit et al., 1993, Chemical stability of liposomes: implications for their physical stability, Chemistry and Physics of Lipids, 64:3-18. [cited by applicant]
Grit et al., Apr. 1993, Hydrolysis of saturated soybean phosphatidylcholine in aqueous liposome dispersions, Journal of Pharmaceutical Sciences, 82(4): 362-366. [cited by applicant]
Gruner et al., “Novel Multilayered Lipid Vesicles: Comparison of Physical Characteristics of Multilamellar Liposomes and Stable Plurilamellar Vesicles,” Biochemistry, 1985, 24(12):2833-2842. [cited by applicant]
Holdich et al., “The variation of crossflow filtration rate with wall shear stress and the effect of deposit thickness,” Chemical Engineering Research and Design (Trans IChem), 1995, 73(part A):20-26. [cited by applicant]
Huang, “Studies on Phosphatidylcholine Vesicles. Formation and Physical Characteristics,” Biochemistry, 1969, 8(1):344-352. [cited by applicant]
Huang, et al., “Determination of phospholipid and fatty glyceride in liposome by RP-HPLC with capacitively coupled contactless conductivity detector,” Analytical Methods, 2018, 10, 4978-4984. [cited by applicant]
Ishii, “Production and size control of large unilamellar liposomes by emulsification,” Liposome Technology 2.sup.nd Edition, pp. 111-121, vol. 1, Gregory Gregoriadis ed., CRC Press, 1993, Boca Raton, FL. [cited by applicant]
Jaffrin et al., “Energy saving pulsatile mode cross flow filtration,” J. Membrane Sci., 1994, 86:281-290. [cited by applicant]
Johnson et al., “New nozzle improves FCC feed atomization, unit yield patterns,” Oil and Gas Journal, 1994, 92(3):80-86. [cited by applicant]
Joshi et al., “The safety of liposome bupivacaine following various routes of administration in animals” [cited by applicant]
Kawashima et al., “Shear-Induced Phase Inversion and Size Control of Water/Oil/Water Emulsion Droplets with Porous Membrane,” J. Colloid Interface Sci., 1991, 145(2):512-523. [cited by applicant]
Kim et al., 1981, Preparation of cell-size unilamellar liposomes with high captured volume and defined size distribution, Biochim. Biophys. Acta, 646:1-9. [cited by applicant]
Kim et al., 1983, Preparation of Multivesicular Liposomes, Biochim. Biophys. Acta, 728(3):339-348. [cited by applicant]
Kim et al., 1985, Preparation of multilamellar vesicles of defined size-distribution by solvent-spherule evaporation, Biochim. Biophys. Acta, 812:793-801. [cited by applicant]
Kim et al., 1987, Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes, Cancer Chemother. Pharmacol., 19(4):307-310. [cited by applicant]
Kim et al., 1987, Multivesicular Liposomes Containing 1-beta-D-Arabinofuranosylcytosine for Slow-Release Intrathecal Therapy, Cancer Res., 47(15):3935-3937. [cited by applicant]
Kim et al., 1987, Multivesicular Liposomes Containing Cytarabine Entrapped in the Presence of Hydrochloric Acid for Intracavitary Chemotherapy, Cancer Treat. Rep., 71(7-8):705-711. [cited by applicant]
Kim et al., 1987, Multivesicular Liposomes Containing Cytarabine for Slow-Release Sc Administration, Cancer Treat. Rep., 71(5):447-450. [cited by applicant]
Kim et al., 1990, Direct Cerebrospinal Fluid Delivery of an Antiretroviral Agent Using Multivesicular Liposomes, J. Infect. Dis., 162(3):750-752. [cited by applicant]
Kim et al., 1993, Extended CSF Cytarabine Exposure Following Intrathecal Administration of DTC 101, J. Olin. Oncol., 11(11):2186-2193. [cited by applicant]
Kim et al., 1993, Extended-release formulation of morphine for subcutaneous administration, Cancer Chemother. Pharmacol., 33(3):187-190. [cited by applicant]
Kim et al., 1993, Prolongation of Drug Exposure in Cerebrospinal Fluid by Encapsulation into DepoFoam, Cancer Res., 53(7):1596-1598. [cited by applicant]
Kim, 1993, Liposomes as Carriers of Cancer Chemotherapy: Current status and Future Prospects, Drugs, 46(4):618-638, 1993. [cited by applicant]
Lafont et al. “Use of Liposome-Associated Bupivacaine for the Management of a Chronic Pain Syndrome,” Anesth. Analg., 1994, 79:818. [cited by applicant]
Lafont et al. “Use of Liposome-Associated Bupivacaine in a Cancer Pain Syndrome,” Anaesthesia, 1996, 51:578-579. [cited by applicant]
Legros et al. “Influence of Different Liposomal Formulations on the Pharmacokinetics of Encapsulated Bupivacaine,” [Abstract]. Anesthesiology, 1990, 73: A851. [cited by applicant]
Liposome Drug Products. Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug … [cited by applicant]
Maa et al., “Liquid-liquid emulsification by rotor/stator homogenization,” J. Controlled Release, 1996, 38:219-228. [cited by applicant]
Maestre et al., “Contribution of Light Scattering to the Circular Dichroism of Deoxyribonucleic Acid Films, Deoxyribonucleic Acid-Polylysine Complexes, and Deoxyribonucleic Acid Particles in Ethanolic Buffers,” Biochemi… [cited by applicant]
Malinovsky et al., “Neurotoxilogical Assessment After Intracisternal Injection of Liposomal Bupivacaine in Rabbits,” Anesth. Analg., 1997, 85:1331-1336. [cited by applicant]
Mancini, “Mastering the mix: Why Leave Mixing to Chance? Get a Proper Mix and a Better Product Every Time,” Food Engineering, Mar. 1996, pp. 79-83. [cited by applicant]
Maranges et al., “Crossflow Filtration of [cited by applicant]
Mashimo et al. “Prolongation of Canine Epidural Anesthesia by Liposome Encapsulation of Lidocaine,” Anesth. Analg., 1992, 74:827-834. [cited by applicant]
Matsumoto et al., “An Attempt at Preparing Water-in-Oil-in-Water Multiple-Phase Emulsions,” J. Colloid Interface Sci., 1976, 57(2):353-361. [cited by applicant]
Meissner et al., Application of High Frequency Backpulsing in Diafiltration of Multivesicular Liposomes, North American Membrane Society, Proceedings, 9.sup.th Annual Meeting, May 31-Jun. 4, 1997, Baltimore, MD, (1997).… [cited by applicant]
Meissner et al., Application of Unsteady Flow Patterns in Permeate and Retentate for the Diafiltration of Multivesicular Lipid Based Particles, Annual AlChE Meeting, Nov. 16-21, 1997, Los Angeles, CA. Unpublished confer… [cited by applicant]
Michaels et al., “Sparging and Agitation-Induced Injury of Cultured Animal Cells: Do Cell-to-Bubble Interactions in the Bulk Liquid Injure Cells?” Biotechnol. Bioeng., 1996, 51(4):399-409. [cited by applicant]
Mutsakis et al., “Advances in Static Mixing Technology,” Chem. Eng. Prog, Jul. 1986, pp. 42-48. [cited by applicant]
Narhi et al., “Role of Native Disulfide Bonds in the Structure and Activity of Insulin-like Growth Factor 1: Genetic Models of Protein-Folding Intermediates,” Biochemistry, 1993, 32(19):5214-5221. [cited by applicant]
Pacira Pharmaceuticals Inc., 2018, Exparel prescribing information, 28 pp. [cited by applicant]
Paul, “Reaction Systems for Bulk Pharmaceutical Production,” Chem. Ind., May 21, 1990, pp. 320-325. [cited by applicant]
Quirk et al., “Investigation of the parameters affecting the separation of bacterial enzymes from cell debris by tangential flow filtration,” Enzyme Microb. Technol. (1984), 6(5):201-206. [cited by applicant]
Radlett, “The Concentration of Mammalian Cells in a Tangential Flow Filtration Unit,” J. Appl. Chem. Biotechnol. (1972), 22:495-499. [cited by applicant]
Redkar et al., “Cross-Flow Microfiltration with High-Frequency Reverse Filtration,” AlChE Journal, 1995, 41(3):501-508. [cited by applicant]
Richard et al., 2011, The safety and tolerability evaluation of DepoFoam, bupivacaine (bupivacaine extended-release liposome injection) administered by incision would infiltration in rabbits and dogs, Expert Opinion on … [cited by applicant]
Ripperger, et al., “Crossflow microfiltration—state of the art,” Separation and Purification Technology, 26 (2002), 19-31. [cited by applicant]
Rodgers et al., “Reduction of Membrane Fouling in the Ultrafiltration of Binary Protein Mixtures,” AlChE Journal, 1991, 37(10):1517-1528. [cited by applicant]
Roy et al., “Multivesicular liposomes containing bleomycin for subcutaneous administration,” Cancer Chemother. Pharmacol., 28(2):105-108, 1991. [cited by applicant]
Russack et al., “Quantitative Cerebrospinal Fluid Cytology in Patients Receiving Intracavitary Chemotherapy,” Ann. Neurol., 1993, 34(1):108-112. [cited by applicant]
Saberi et al., “Bubble Size and Velocity Measurement in Gas-Liquid Systems: Application of Fiber Optic Technique to Pilot Plant Scale,” Can. J. Chem. Eng., 1995, 73: 253-257. [cited by applicant]
Shakiba et al., “Evaluation of Retinal Toxicity and Liposome Encapsulation of the Anti-CMV drug 2′-nor-cyclic GMP,” Invest. Ophthalmol. Vis. Sci., 34(10):2903-2910, 1993. [cited by applicant]
Skuta et al., “Filtering Surgery in Owl Monkeys Treated with the Antimetabolite 5-Fluorouridine 5′ Monophosphate Entrapped in Multivesicular Liposomes,” Am. J. Ophthmalmol., 1987, 103(5):714-716. [cited by applicant]
Streiff et al., “Don't overlook static-mixer reactors,” Chem. Eng., Jun. 1994, pp. 76-82. [cited by applicant]
Szoka et al., “Comparative properties and methods of preparation of lipid vesicles (liposomes),” Ann. Rev. Biophys. Bioeng., 1980, 9:467-508. [cited by applicant]
Tanaka et al., “Crossflow Filtration of Baker's Yeast with Periodical Stopping of Permeation Flow and Bubbling,” Biotechnol. Bioeng., 1995, 47(3):401-404. [cited by applicant]
Thompson, G.A. Jr., The Regulation of Membrane Lipid Metabolism 2.sup.nd Ed., CRC Press: Boca Raton, pp. 1-20 (1992). [cited by applicant]
Tsuchiya et al., “Tortuosity of Bubble Rise Path in a Liquid-Solid Fluidized Bed: Effect of Particle Shape,” AlChE Journal, 1995, 41(6):1368-1374. [cited by applicant]
Turski et al., “Magnetic Resonance Imaging of Rabbit Brain after Intracarotid Injection of Large Multivesicular Liposomes Containing Paramagnetic Metals and DTPA,” Magn. Reson. Med., 7(2):184-196, 1998. [cited by applicant]
Watts et al., “Microencapsulation Using Emulsification/Solvent Evaporation: An Overview of Techniques and Applications,” Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7(3):235-259. [cited by applicant]
Zheng et al., “FDA Bioequivalence Standards, Chapter 11, Bioequivalence for Liposomal Drug Products,” AAPS Advances in the Pharmaceutical Sciences, vol. 13, 2014, 275-296. [cited by applicant]
Sep. 30, 2021 Redacted letter regarding bupivacaine liposome injectable suspension ANDA No. 214348, Paragraph IV Notice Letter Invalidity contentions for U.S. Pat. No. 11,033,495. [cited by applicant]
Dec. 28, 2021 Redacted letter regarding bupivacaine liposome injectable suspension ANDA No. 214348, Paragraph IV Notice Letter Invalidity contentions for U.S. Pat. No. 11,179,336. [cited by applicant]
Apr. 14, 2023 Redacted letter regarding bupivacaine liposome injectable suspension ANDA No. 214348, Paragraph IV Notice Letter invalidity contentions for U.S. Pat. Nos., 11,278,494; 11,311,486; 11,304,904; 11,357,727; 1… [cited by applicant]
Mar. 11, 2024 Redacted letter regarding bupivacaine liposome injectable suspension ANDA No. 214348 Notice of Paragraph IV certification and invalidity contentions for U.S. Pat. Nos. 11,819,574 and 11,819,575 (57 pp). [cited by applicant]
May 24, 2024 Redacted letter regarding bupivacaine liposome injectable suspension ANDA No. 214348 Notice of Paragraph IV certification and invalidity contentions for U.S. Pat. No. 11,925,706 (30 pp). [cited by applicant]
Chahar et al., 2012, Liposomal bupivacaine: a review of a new bupivacaine formulation, Journal of Pain Research, 5:257-264. [cited by applicant]
National Institute of Drug Abuse, Jun. 2021, Prescription Opioids Drug Facts, 9 pp. [cited by applicant]
Rabin, Apr. 6, 2018, FDA in brief: FDA approves new use of Exparel for nerve block pain relief following shoulder surgeries, Media Inquiries, 3 pp. [cited by applicant]
Pacira Pharmaceuticals, Inc. Mar. 22, 2021, Pacira announces FDA approval of supplemental new drug allocation for EXPAREL® (bupivacaine liposome injectable suspension) in pediatric patients, press release, 4 pp. [cited by applicant]
Malik et al., 22017, Emerging roles of liposomal bupivacaine in anesthesia practice, Journal of Anaesthesiology Clinical Pharmacology, 33:151-156. [cited by applicant]
Salehi et al., 2020, Multivesicular liposome (Depofoam) in human disease, Iranian Journal of Pharmaceutical Research, 19(2):9-21. [cited by applicant]
Lee et al., Mar. 19, 2015, Modernizing pharmaceutical manufacturing: from batch to continuous productions, J. Pharm. Innov. DOI 10.1007/s12247-015-9215-8, 11 pp. [cited by applicant]
Process Facilities Group, LLC Novo Nordisk Buildings 1 & 9 New Process (archived webpage) retrieved on Sep. 20, 2022, 4 pp. [cited by applicant]
Pacira BioSciences, Inc., Aug. 2, 2017, Pacira Pharmaceuticals (PCRX) Q2 2017 results—earnings call transcript, 21 pp. [cited by applicant]
Pacira BioSciences, Inc., Aug. 2, 2018, Pacira Pharmaceuticals (PCRX) Q2 2018 results—earnings call transcript, 24 pp. [cited by applicant]
Pacira BioSciences, Inc., Aug. 8, 2019, Pacira Pharmaceuticals (PCRX) Q2 2019 results—earnings call transcript, 21 pp. [cited by applicant]
Pacira BioSciences, Inc., 2022, Non-opioid Exparel reduces the need for opioids, project brochure, https://www.exparel.com/patients/non-opioid-pain-medication, downloaded Oct. 27, 2022, 4 pp. [cited by applicant]
Pacira Pharmaceuticals, Inc., at Jefferies Global Healthcare Conference, Jun. 3, 2013, FD (Fair Disclosure) Wire, 8 pp. [cited by applicant]
US Dept. Health and Human Services, Food and Drug Administration, Jan. 2011, Guidance for Industry, Process Validation: general Principles and Practices, 23 pp. [cited by applicant]
Pacira Pharmaceuticals, Inc., Oct. 25, 2022, Pacira Pharmaceuticals, Inc., announces commercial availability of Exparel® News Release, 7 pp. [cited by applicant]
Pacira BioSciences, Inc., Jan. 7, 2021, Pacira reports record revenue for 2020 of $429.6 million, press release, 3 pp. [cited by applicant]
Pacira BioSciences, Inc., Feb. 28, 2019, Pacira reports record fourth quarter and full year revenues, press release, 8 pp. [cited by applicant]
Department of Health and Human Services, Food and Drug Administration, Feb. 2012, Patent & Exclusivity Drug Product List, Cumulative Supplement 2, 3 pp. [cited by applicant]
Department of Health and Human Services, Food and Drug Administration, Jun. 2012, Patent & Exclusivity Drug Product List, Cumulative Supplement 6, 3 pp. [cited by applicant]
Department of Health and Human Services, Food and Drug Administration, Oct. 2014, Patent & Exclusivity Drug Product List, Cumulative Supplement 10, 3 pp. [cited by applicant]
Department of Health and Human Services, Food and Drug Administration, Dec. 2015, Patent & Exclusivity Drug Product List, Cumulative Supplement 12, 3 pp. [cited by applicant]
Department of Health and Human Services, Food and Drug Administration, Mar. 2017, Patent & Exclusivity Drug Product List, Cumulative Supplement 3, 3 pp. [cited by applicant]
Department of Health and Human Services, Food and Drug Administration, Jul. 2021, Patent & Exclusivity Drug Product List, Cumulative Supplement 7, 3 pp. [cited by applicant]
Department of Health and Human Services, Food and Drug Administration, Nov. 2021, Patent & Exclusivity Drug Product List, Cumulative Supplement 11, 3 pp. [cited by applicant]
Crommelin et al., Hydrolysis of phospholipids in liposomes and stability-indicating analytical techniques, in Gregoriadis, ed., Liposome Technology, 2007 (Third Edition) CRC Press, Boca Raton, FL, pp. 285-295. [cited by applicant]
European Medicines Agency, Committee for Medicinal Products for Human Use, Sep. 17, 2020, Assessment report: Exparel liposomal, 147 pp. [cited by applicant]
Ilfeld, Liposomal bupivacaine: its role in regional anesthesia and postoperative analgesia, Advances in Anesthesia, 2014, 32:133-147. [cited by applicant]
Kharitonov, A review of the compatibility of liposome bupivacaine with other drug products and commonly used implant materials, Postgraduate Medicine, 2014, 126(1):129-138. [cited by applicant]
Li et al., Multivesicular liposomes for the sustained release of angiotensin I-converting enzyme (ACE) inhibitory peptides from peanuts: design, characterization, and in vitro evaluation, Molecules, 2019, 24:1746, 15 pp. [cited by applicant]
Aug. 2, 2017, Pacira Pharmaceuticals (PCRX) Q2 2017 Results—Earnings Call Transcript, https://seekingalpha.com/article/4093713-pacira-pharmaceuticals-pcrx-g2-2017-results-earningscall-transcript; accessed on Apr. 17, 20… [cited by applicant]
Pacira Pharmaceuticals, Inc., U.S. Securities and Exchange Commission, Form 10-K, for fiscal year ended Dec. 31, 2018, 102 pp. [cited by applicant]
Wang et al., Multivesicular liposome (MVL) sustained delivery of a n ovel synthetic cationic GnRH antagonist for prostate cancer treatment, Journal of Pharmacy and Pharmacology, 2011, 63:904-910. [cited by applicant]
Yadav et al., Stability aspects of liposomes, Indian Journal of Pharmaceutical Education and Research, 2011, 45(4):402-413. [cited by applicant]
Yu et al., 2023, Characterization of Exparel bupivacaine multivesicular liposomes, International Journal of Pharmaceutics, 639: 122952, 6 pp. [cited by applicant]
Bulbake et al., 2017, Liposomal Formulations in Clinical Use: An Updated Review, Pharmaceutics, 9(12):1-33. [cited by applicant]
Lu et al., 2001, Preparation and characterization of bupivacaine multivesicular liposome: A QbD study about the effects of formulation and process on critical quality attributes, International Journal of Pharmaceutics, … [cited by applicant]
Manna et al., 2019, Proving the mechanism of bupivacaine drug release from multivesicular liposomes, Journal of Controlled Release, 294:279-287. [cited by applicant]
Mayat et al., Jun. 30, 1973, The Use of Marcaine for Epidural Anaesthesia, S. Afr. Med. J., 47:1112-1114. [cited by applicant]
Mayne et al., 2019, Towards experimental P-systems using multivesicular liposomes, Journal of Membrane Computing, 1:20-28. [cited by applicant]
Physician's Desk Reference, 2013, Julie Cross ed., 67th ed., Exparel, pp. 311, 2128-2131. [cited by applicant]
U.S. Department of Health and Human Services., Office of Generic Drug Policy, 2020, excerpt from Approved Drug Products with Therapeutic Equivalence Evaluations at ADA 34 (40th Ed. 2020), 7 pp. [cited by applicant]
U.S. Food & Drug Admin., Nov. 2003, Guidance for Industry, Q1A(R2) Stability Testing of New Drug Substances and Products, 25 pp. [cited by applicant]
Ye et al., 2000, DepoFoam™ technology: a vehicle for controlled delivery of protein and peptide drugs, Journal of Controlled Release, 64:155-166. [cited by applicant]
Zhang et al., 2000, Effect of pH, Ionic Strength and Oxygen Burden on the Chemical Stability of EPC/Cholesterol Liposomes Under Accelerated Conditions Part 1: Lipid Hydrolysis, Eur. J of Pharmaceutics and Biopharmaceuti… [cited by applicant]
Complaint for Patent Infringement of U.S. Pat. No. 12,156,940 filed Dec. 3, 2024 by Pacira Pharmaceuticals, Inc., and Pacira Biosciences, Inc., in the United States District Court for the Northern District of Illinois, … [cited by applicant]
Complaint for declaratory judgment of noninfringement and invalidity of U.S. Pat. No. 12,156,940 filed Dec. 10, 2024 by eVenus Pharmaceutical Labs. Inc. and Jiangsu Hengrui Pharmaceuticals Co., Ltd. in the United States… [cited by applicant]
Cited By (1)
US 12,370,142